WO2010039381A1 - Transdermal extended-delivery donepezil compositions and methods for using the same - Google Patents
Transdermal extended-delivery donepezil compositions and methods for using the same Download PDFInfo
- Publication number
- WO2010039381A1 WO2010039381A1 PCT/US2009/055542 US2009055542W WO2010039381A1 WO 2010039381 A1 WO2010039381 A1 WO 2010039381A1 US 2009055542 W US2009055542 W US 2009055542W WO 2010039381 A1 WO2010039381 A1 WO 2010039381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active agent
- donepezil active
- donepezil
- composition according
- extended delivery
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims abstract description 203
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 229960003530 donepezil Drugs 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000013543 active substance Substances 0.000 claims abstract description 128
- 239000000853 adhesive Substances 0.000 claims description 31
- 230000001070 adhesive effect Effects 0.000 claims description 30
- 229920001577 copolymer Polymers 0.000 claims description 18
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 239000003623 enhancer Substances 0.000 claims description 14
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 11
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical group CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002884 Laureth 4 Polymers 0.000 claims description 4
- 229940061515 laureth-4 Drugs 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 3
- 229940100556 laureth-23 Drugs 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 13
- 210000003491 skin Anatomy 0.000 description 49
- 239000010410 layer Substances 0.000 description 32
- 239000000178 monomer Substances 0.000 description 16
- -1 rivastigimine Chemical compound 0.000 description 16
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000000123 paper Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000010408 film Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 229920001225 polyester resin Polymers 0.000 description 3
- 239000004645 polyester resin Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000002205 anti-dementic effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229960003135 donepezil hydrochloride Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000011086 glassine Substances 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 239000011112 polyethylene naphthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005672 polyolefin resin Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008337 systemic blood flow Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- CHNGPLVDGWOPMD-UHFFFAOYSA-N 2-ethylbutyl 2-methylprop-2-enoate Chemical compound CCC(CC)COC(=O)C(C)=C CHNGPLVDGWOPMD-UHFFFAOYSA-N 0.000 description 1
- JGRXEBOFWPLEAV-UHFFFAOYSA-N 2-ethylbutyl prop-2-enoate Chemical compound CCC(CC)COC(=O)C=C JGRXEBOFWPLEAV-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- YXYJVFYWCLAXHO-UHFFFAOYSA-N 2-methoxyethyl 2-methylprop-2-enoate Chemical compound COCCOC(=O)C(C)=C YXYJVFYWCLAXHO-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NQSLZEHVGKWKAY-UHFFFAOYSA-N 6-methylheptyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C(C)=C NQSLZEHVGKWKAY-UHFFFAOYSA-N 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 description 1
- FWLDHHJLVGRRHD-UHFFFAOYSA-N decyl prop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C=C FWLDHHJLVGRRHD-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 238000013148 permeation assay Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229920006029 tetra-polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KEROTHRUZYBWCY-UHFFFAOYSA-N tridecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C(C)=C KEROTHRUZYBWCY-UHFFFAOYSA-N 0.000 description 1
- XOALFFJGWSCQEO-UHFFFAOYSA-N tridecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C=C XOALFFJGWSCQEO-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- Alzheimer's disease is a degenerative brain disease that causes dementia, a progressive decline in cognitive function beyond what might be expected from normal aging. Short-term memory loss is the most common symptom, and later symptoms include confusion, anger, mood swings, language breakdown, long-term memory loss, and the general withdrawal of the subject as his or her senses decline. Alzheimer's disease has no current cure, however its symptoms can be treated with active agents, such as acetylcholinesterase inhibitors (e.g., donepezil, galantamine, rivastigimine, tacrine, etc.) and N-methyl D-aspartate (NMDA) receptor antagonists (e.g., memantine).
- Donepezil known chemically as ( ⁇ )-2,3-dihydro-5,6-dimethoxy-2-[[1 -
- Transdermal active agent formulations also known as transdermal patches or skin patches, are adhesive patches containing an active agent that are placed on the skin to deliver the active agent through the skin. Transdermal patches deliver the active agent by percutaneous absorption, which is the absorption of substances through unbroken skin.
- the active agent contained in the patch passes through, or permeates the skin and can reach its site of action through a systemic blood flow.
- the transdermal patch may be placed on the desired treatment site such that the medication contained in the patch is delivered topically.
- a transdermal extended-delivery donepezil active agent composition is provided. Aspects of the compositions of the invention include a donepezil active agent layer that is formulated to provide for multi-day delivery of a therapeutically effective amount of a donepezil active agent to a subject when the composition is topically applied to the subject. Also provided are methods of using the formulations, e.g., for administering a donepezil active agent to a subject, and kits containing the formulations.
- Figure 1 shows a cross sectional view of an embodiment of the transdermal active agent formulation described herein.
- a transdermal extended-delivery donepezil active agent composition is provided. Aspects of the compositions of the invention include a donepezil active agent layer that is formulated to provide for multi-day delivery of a therapeutically effective amount of a donepezil active agent to a subject when the composition is topically applied to the subject. Also provided are methods of using the formulations, e.g., for administering donepezil active agent to a subject, and kits containing the formulations.
- transdermal donepezil compositions are reviewed first in greater detail, followed by a detailed description of methods of using the compositions and a review of kits that include the transdermal formulations.
- compositions of the invention include a donepezil active agent layer, wherein the donepezil active agent layer is formulated to provide for multi-day delivery of a therapeutically effective amount of a donepezil active agent to a subject when said composition is topically applied to said subject.
- multi-day delivery is meant that the layer is formulated to provide a therapeutically effective amount to a subject when the composition is applied to a skin site of a subject for a period of time that is 2 days or longer, e.g., 3 days or longer, such as 5 days or longer, including 7 days or longer, such as 10 days or longer.
- compositions when applied to a skin site of a subject during its intended time of application, e.g., within 7 days of application, provides for a systemic amount of donepezil that provides a desired therapeutic activity.
- the compositions provide delivery of a target dosage of donepezil that is 5 mg/day or greater over a one week period (i.e., 7 days or 168 hours), including 10 mg/day or greater over one week, such as 15 mg/day or greater over one week.
- the active agent compositions of embodiments of the invention are formulated to provide for high skin permeation rates, e.g., as determined using the skin permeation assay reported in the Experimental Section, below.
- skin permeation rates of 1 .5 ⁇ g/cm 2 /hr or greater such as 2.5 ⁇ g/cm 2 /hr or greater, including 3.5 ⁇ g/cm 2 /hr or greater are provided by the compositions.
- the size (i.e., area) of the transdermal compositions may vary.
- the size of the composition is chosen in view of the desired transdermal flux rate of the active agent and the target dosage. For example, if the transdermal flux is 3.4 ⁇ g/cm 2 /hr and the target dosage is 5 mg/day, then the transdermal composition is chosen to have an area of about 43 cm 2 . Or for example, if the transdermal flux is 3.4 ⁇ g/cm 2 /hr and the target dosage is 10 mg/day, then the transdermal patch is chosen have an area of about 87 cm 2 .
- the compositions have dimensions chosen to cover an area of skin when applied to a skin site that ranges from 10 to 200, such as 20 to 150, including 40 to 140 cm 2 .
- the donepezil active agent layer of the compositions may vary in thickness. In some instances, the thickness of the active agent layer ranges from 25 to 250, such as 50 to 200, including 100 to 150 micrometers in thickness.
- the compositions of the invention include a donepezil active agent layer, a backing layer and release liner.
- FIG. 1 a composition 1 according to an embodiment of the invention, where the composition 1 includes a backing layer 2, a donepezil active agent layer 3, and a release liner 4. Each of these layers is now described in greater detail.
- the donepezil active agent layer of compositions of the invention includes a donepezil active agent.
- donepezil active agent is meant donepezil freebase or a salt thereof, e.g., donepezil hydrochloride.
- Donepezil freebase has the empirical formula of C 24 H 29 NO 3 and the IUPAC name ( ⁇ )-2,3-dihydro-5,6-dimethoxy-2-[[1 - (phenylmethyl)-4-piperidinyl]methyl]-1 H-inden-1 -one.
- Donepezil has the following chemical structure:
- Salts of donepezil may include the hydrochloride salt, and the like.
- Donepezil hydrochloride salt, or donepezil-HCI has the empirical formula of C 24 H 2 QN(VHCI and the IUPAC name ( ⁇ )-2,3-dihydro-5,6-dimethoxy-2-[[1 -(phenylmethyl)-4- piperidinyl]methyl]-1 H-inden-1 -one hydrochloride.
- Donepezil-HCI has the following chemical structure:
- the amount of donepezil active agent present in the donepezil active agent layer is sufficient to provide for the desired extended delivery of donepezil to a subject when applied to a skin site of a subject.
- the donepezil active agent layer includes a donepezil active agent in an amount ranging from 10% to 35% (w/w), such as 15 to 30% (w/w), including 20 to 25% (w/w).
- the donepezil active agent layer is free of solid and un- dissolved donepezil active agent. This means that the donepezil active agent layer does not include crystalline or other solid forms of the donepezil active agent, or donepezil active agent that is not present in the composition.
- embodiments of the donepezil active agent layer include a percutaneous absorption enhancer.
- Percutaneous absorption enhancers employed in embodiments of the compositions facilitate the absorption of the donepezil active agent by the skin of the subject. Accordingly, the percutaneous absorption enhancer may also be referred to as a percutaneous permeation enhancer because it may facilitate not only the percutaneous absorption of the active agent, but also the percutaneous permeation of the active agent through the skin of the subject.
- percutaneous absorption enhancers are polyoxyethers of alcohols, such as but not limited to polyoxyethers of aliphatic alcohols, including saturated or unsaturated higher alcohols, e.g., having 8 to 22 carbon atoms, such as oleyl alcohol and lauryl alcohol.
- the percutaneous absorption enhancer is described by the formula: C m H 2 m + i (OCH 2 CH 2 )nOH wherein: m is an integer ranging from 8 to 22, such as 8 to 18; and n is an integer ranging from 2 to 25, such as 2 to 23.
- Specific percutaneous absorption enhancers of interest include laureth-4 and laureth-23, as well as combinations thereof.
- the donepezil active agent layer contains the percutaneous absorption enhancer in an amount ranging from 2% to 25% (w/w), such as from 10% to 25% (w/w), and including from 15% to 25% (w/w), where 15% (w/w) is present in certain embodiments.
- the transdermal donepezil composition of the invention is provided in an adhesive format, such as an adhesive tape or an adhesive patch.
- the donepezil active agent layer is an adhesive layer, such that when the composition is applied to a skin surface the composition is adhered to a skin surface by the adhesion of the active agent layer to the skin surface.
- the donepezil active agent layer includes a pressure-sensitive adhesive.
- pressure-sensitive adhesive means an adhesive that forms a bond when pressure is applied to adhere the adhesive with a surface.
- the adhesive is one in which no solvent, water, or heat is needed to activate the adhesive.
- Pressure sensitive adhesives of interest include, but are not limited to acrylate copolymers.
- Acrylate copolymers of interest include copolymers of various monomers which may be "soft" monomers, "hard” monomers, and optionally
- the acrylate copolymers can be composed of a copolymer including bipolymer (i.e., made with two monomers), a terpolymer (i.e., made with three monomers), or a tetrapolymer (i.e., made with four monomers), or copolymers made from even greater numbers of monomers.
- the acrylate copolymers can include cross-linked and non-cross-linked polymers. The polymers can be cross-linked by known methods to provide the desired polymers.
- Monomers from which the acrylate copolymers are produced include at least two or more exemplary components selected from the group including acrylic acids, alkyl acrylates, methacrylates, copolymerizable secondary monomers or monomers with functional groups.
- Monomers ("soft" and "hard” monomers) of interest include, but are not limited to, methoxyethyl acrylate, ethyl acrylate, butyl acrylate, butyl methacrylate, hexyl acrylate, hexyl methacrylate, 2-ethylbutyl acrylate, 2-ethylbutyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2- ethylhexyl methacrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl
- acrylic adhesive monomers are described in Satas, "Acrylic Adhesives," Handbook of Pressure-Sensitive Adhesive Technology, 2nd ed., pp. 396-456 (D. Satas, ed.), Van Nostrand Reinhold, New York (1989).
- acrylate copolymers that include polar functional monomeric residues.
- monomeric residues that provide for -COOH functional groups.
- Useful carboxylic acid monomers to provide the -COOH functional group may contain from about 3 to about 6 carbon atoms and include, among others, acrylic acid, methacrylic acid, itaconic acid, and the like. Acrylic acid, methacrylic acid and mixtures thereof are employed in certain embodiments acids.
- the functional monomer(s) are present in certain embodiments of the copolymers in an amount of 2 wt% or more, such as between 3-10 wt%.
- the adhesive may have a composition that is, or is substantially the same as, the composition of DuroTak ® 87-2852 (National Adhesives, Bridgewater, NJ).
- the term "substantially the same” as used herein refers to a composition that is an acrylate-vinyl acetate copolymer in an organic solvent solution and provides for the functionality as described herein.
- the acrylic pressure-sensitive adhesive is DuroTak ® 87-2852.
- the adhesive may have a composition that is, or is substantially the same as, the composition of DuroTak ® 87-2054 (National Adhesives, Bridgewater, NJ).
- the term "substantially the same” as used herein refers to a composition that is an acrylate-vinyl acetate copolymer in an organic solvent solution and provides for the functionality as described herein.
- the acrylic pressure-sensitive adhesive is DuroTak ® 87-2054.
- the adhesive may have a composition that is, or is substantially the same as, the composition of DuroTak ® 87-2196 (National Adhesives, Bridgewater, NJ).
- the term "substantially the same” as used herein refers to a composition that is an acrylate-vinyl acetate copolymer in an organic solvent solution and provides for the functionality as described herein.
- the acrylic pressure-sensitive adhesive is DuroTak ® 87-2196.
- polyacrylate-based adhesives of interest are as follows, identified as product numbers, manufactured by National Starch (DURO-TAK ® is a trademark of National Starch adhesives): 87-200A, 87-2353, 87-2100, 87-2051 , 87- 2052, 87-2194, 87-2677, 87-201 A, 87-2979, and 87-2074.
- DURO-TAK ® is a trademark of National Starch adhesives
- compositions of the invention may include a backing layer.
- the backing may be flexible to an extent that it can be brought into close contact with a skin surface.
- the backing is such that it does not absorb the active agent, and does not allow the active agent to be released from the backing side.
- the backing may include, but is not limited to, non-woven fabrics, fabrics, films (including sheets), porous bodies, foamed bodies, paper, composite materials obtained by laminating a film on a non-woven fabric or fabric, and combinations thereof.
- Non-woven fabric may include, but is not limited to the following: polyolefin resins such as polyethylene and polypropylene; polyester resins such as polyethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate; and besides rayon, polyamide, poly(ester ether), polyurethane, polyacrylic resins, polyvinyl alcohol, styrene-isoprene-styrene copolymers, and styrene-ethylene-propylene-styrene copolymers; and combinations thereof.
- Fabric may include, but is not limited to cotton, rayon, polyacrylic resins, polyester resins, polyvinyl alcohol, and combinations thereof.
- the film may include, but is not limited to the following: polyolefin resins such as polyethylene and polypropylene; polyacrylic resins such as polymethyl methacrylate and polyethyl methacrylate; polyester resins such as polyethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate; and besides cellophane, polyvinyl alcohol, ethylene-vinyl alcohol copolymers, polyvinyl chloride, polystyrene, polyurethane, polyacrylonitrile, fluororesins, styrene-isoprene-styrene copolymers, styrene-butadiene rubber, polybutadiene, ethylene-vinyl acetate copolymers, polyamide, and polysulfone; and combinations thereof.
- polyolefin resins such as polyethylene and polypropylene
- polyacrylic resins such as polymethyl methacrylate and polyethyl methacryl
- the paper may include, but is not limited to impregnated paper, coated paper, wood free paper, Kraft paper, Japanese paper, glassine paper, synthetic paper, and combinations thereof.
- Composite materials may include, but are not limited to composite materials obtained by laminating the above-described film on the above- described non-woven fabric or fabric.
- a release liner is provided on the donepezil active agent layer, and specifically on a surface of the active agent layer that is distal (i.e. opposite) from the backing layer, if present.
- the release liner facilitates the protection of the active agent layer.
- the release liner may be prepared by treating one side of polyethylene-coated wood free paper, polyolefin-coated glassine paper, a polyethylene terephthalate (polyester) film, a polypropylene film, or the like with a silicone treatment.
- an adhesive overlay can be used to increase the adhesion of the composition when applied to the skin.
- Adhesive overlays can include a layer of adhesive present on a backing material, such as a porous, non-porous, occlusive, or breathable backing material.
- the dimensions of the adhesive overlay are chosen to provide the desired functionality, where in some instances the dimensions are chose such that the adhesive overlay, when applied over the active agent formulation, extends some distance beyond one or more of the sides of the active agent formulation. In some instances, the area of the adhesive overlay exceeds the area of the active agent formulation by 5% or more, such as by 10% or more, including by 20% or more.
- the adhesive overlay can be applied by the patients, by the care givers, or can be integrated in the kits.
- the methods include applying to a skin site of the subject a transdermal donepezil active agent composition of the invention, e.g., as described in detail above, and maintaining the composition at the skin site of the subject for a period of time sufficient to deliver the donepezil active agent to the subject.
- the transdermal active agent composition may be applied to the skin of the subject, for example at a skin site, a keratinized skin site, etc.
- the transdermal active agent composition may be applied to a skin surface of a desired skin site such that the composition is adhered to the skin surface by the adhesion of the active agent layer to the skin surface.
- the transdermal active agent composition may be applied to a skin site for an amount of time sufficient to deliver the donepezil active agent to the subject. In some cases, the transdermal active agent composition may be applied to the skin site for an amount of time sufficient to deliver an effective amount of the donepezil active agent to the subject.
- the term "effective amount" means a dosage sufficient to provide the desired result. For example, an effective amount may be an amount of the donepezil active agent present in the composition that is sufficient such that, when applied to a skin site in accordance with the methods described herein, the subject's symptoms associated with Alzheimer's disease and/or dementia are alleviated at least to some measurable extent (e.g., as determined by using any convenient art accepted assay), if not completely diminished.
- the transdermal active agent composition may be applied to the skin site for an amount of time sufficient to deliver a target dose of the active agent to the subject over a period of time.
- the target dose that is delivered may be one that provides for a systemic level of active agent that is sufficient to provide the desired activity with respect to the target disease, e.g., Alzheimer's.
- the target dose of the active agent may be 5 mg/day or greater, including 10 mg/day or greater, such as 15 mg/day or greater.
- the transdermal active agent composition may be applied to the skin site for an amount of time ranging from 1 day to 14 days, such as 3 days to 10 days, including 7 days to 10 days.
- the transdermal active agent composition may be applied to the skin site for 7 days (i.e., one week). After the transdermal active agent composition has been applied to the skin site for the desired amount of time (i.e., an amount of time sufficient to deliver a target dose of the active agent to the subject over a period of time), the composition may be removed from the skin site. A new transdermal composition may be applied at the same or at a different skin site. The new transdermal composition may be applied to a different skin site to reduce the possible occurrence of skin irritation and/or skin sensitization at the prior site of application.
- the methods described herein may include a diagnostic step.
- Individuals may be diagnosed as being in need of the subject methods using any convenient protocol, and are generally known to be in need of the subject methods, e.g., they are suffering from a target disease condition or have been determined to be at risk for suffering from a target disease condition, prior to practicing the subject methods.
- Diagnosis or assessment of Alzheimer's disease and dementia is well- established in the art. Assessment may be performed based on, but not limited to the following: patient history; collateral history from relatives; diagnostic tests, such as clinical observation of behavior; mental status testing of cognitive functions including but not limited to memory, language, perceptual skills, attention, constructive abilities, orientation, problem solving and functional abilities; physical examinations; neurological examinations; brain imaging, such as but not limited to computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and single photon emission computed tomography (SPECT); and the like.
- CT computed tomography
- MRI magnetic resonance imaging
- PET positron emission tomography
- SPECT single photon emission computed tomography
- transdermal active agent compositions find use in any application where a subject would benefit from being administered an antidementia active agent, such as but not limited to donepezil.
- the compositions are employed in the treatment of a condition.
- treatment is meant that at least an amelioration of the symptoms associated with the condition afflicting the subject is achieved, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the condition being treated.
- treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the subject no longer suffers from the condition, or at least the symptoms that characterize the condition.
- administration of donepezil according to the subject methods can be used to treat diseases or conditions including, but not limited to Alzheimer's disease, dementia, and the like.
- the transdermal active agent composition may be used for administering donepezil to a subject.
- the method includes applying a transdermal active agent composition, as described herein, to a skin surface of a subject.
- the method further includes maintaining the active agent composition on the skin of the subject for a period of time sufficient to deliver the active agent to the subject.
- Subjects of interest include humans.
- the transdermal active agent composition is provided as an adhesive patch and is applied to the skin surface, whereby the active agent in the composition can be administered by percutaneous permeation through the skin.
- the transdermal active agent composition is applied to a skin surface, the active agent permeates the skin in contact with the patch to reach the site of action through a systemic blood flow.
- kits for use in practicing the methods described herein are also provided.
- the kits include a transdermal donepezil active agent composition, e.g., as described above.
- the kits include an adhesive overlay as described above.
- the kits will further include instructions for practicing the subject methods or means for obtaining the same (e.g., a website URL directing the user to a webpage which provides the instructions), where these instructions may be printed on a substrate, where substrate may be one or more of: a package insert, the packaging, reagent containers and the like.
- the one or more components are present in the same or different containers, as may be convenient or desirable.
- Formulations were prepared by mixing stock solutions of each of the mixture components in organic solvents (typically 30-60 wt% solid content in ethyl acetate, methanol and/or ethanol), followed by a mixing process. Once a homogeneous mixture was formed, the solution was cast on a release liner (sliconized polyester sheet of 2-3 mils) and dried at 65° - 8O 0 C for 10-90 minutes. The adhesive films were laminated to a PET backing.
- organic solvents typically 30-60 wt% solid content in ethyl acetate, methanol and/or ethanol
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009300184A AU2009300184A1 (en) | 2008-09-30 | 2009-08-31 | Transdermal extended-delivery donepezil compositions and methods for using the same |
CN200980138160XA CN102164601A (en) | 2008-09-30 | 2009-08-31 | Transdermal extended-delivery donepezil compositions and methods for using the same |
CA2733265A CA2733265A1 (en) | 2008-09-30 | 2009-08-31 | Transdermal extended-delivery donepezil compositions and methods for using the same |
JP2011530087A JP2012504163A (en) | 2008-09-30 | 2009-08-31 | Transdermal sustained delivery donepezil composition and methods of using the composition |
BRPI0917862A BRPI0917862A2 (en) | 2008-09-30 | 2009-08-31 | prolonged distribution transdermal donepezil compositions and methods for using them |
EP09818191A EP2328582A4 (en) | 2008-09-30 | 2009-08-31 | Transdermal extended-delivery donepezil compositions and methods for using the same |
MX2011002260A MX2011002260A (en) | 2008-09-30 | 2009-08-31 | Transdermal extended-delivery donepezil compositions and methods for using the same. |
IL210970A IL210970A0 (en) | 2008-09-30 | 2011-01-31 | Transdermal extended-delivery donepezil compositions and methods for using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10141208P | 2008-09-30 | 2008-09-30 | |
US61/101,412 | 2008-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010039381A1 true WO2010039381A1 (en) | 2010-04-08 |
Family
ID=42057739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/055542 WO2010039381A1 (en) | 2008-09-30 | 2009-08-31 | Transdermal extended-delivery donepezil compositions and methods for using the same |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100080842A1 (en) |
EP (1) | EP2328582A4 (en) |
JP (1) | JP2012504163A (en) |
CN (1) | CN102164601A (en) |
AR (1) | AR073696A1 (en) |
AU (1) | AU2009300184A1 (en) |
BR (1) | BRPI0917862A2 (en) |
CA (1) | CA2733265A1 (en) |
IL (1) | IL210970A0 (en) |
MX (1) | MX2011002260A (en) |
TW (1) | TW201029653A (en) |
WO (1) | WO2010039381A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012043801A1 (en) * | 2010-09-30 | 2012-04-05 | 積水メディカル株式会社 | Patch |
EP2785691A4 (en) * | 2011-11-29 | 2015-09-30 | Ziqiang Gu | Donepezil pamoate, preparation method and its use |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ605352A (en) | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
TWI433904B (en) * | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | Donepezil transdermal patch |
KR101485822B1 (en) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | Transdermal drug delivery system comprising donepezil or its salt |
WO2015127280A1 (en) | 2014-02-20 | 2015-08-27 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
KR101796771B1 (en) * | 2014-12-18 | 2017-11-10 | 아이큐어 주식회사 | Transdermal composition comprising donepezil as an active agent |
KR102033686B1 (en) | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | Microneedle transdermal patch comprising donepezil |
US20190175520A1 (en) * | 2017-12-13 | 2019-06-13 | Corium International, Inc. | Method for depot creation during transdermal drug delivery |
KR102024996B1 (en) | 2017-12-27 | 2019-09-25 | 동아에스티 주식회사 | Percutaneous Absorption Preparation for Treating Dementia Comprising Donepezil |
KR102372630B1 (en) | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | A transdermal preparation comprising a high content of donepezil or a salt thereof |
CN112823793A (en) * | 2019-11-20 | 2021-05-21 | 成都康弘药业集团股份有限公司 | Transdermal patch containing donepezil and preparation method thereof |
WO2024127805A1 (en) * | 2022-12-16 | 2024-06-20 | 帝國製薬株式会社 | Transdermally absorbable donepezil-containing preparation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20050260255A1 (en) * | 2002-08-28 | 2005-11-24 | Takaaki Terahara | Adhesive patch |
US20080044461A1 (en) * | 2006-08-17 | 2008-02-21 | Valia Kirti H | Transdermal methods and systems for treating Alzheimer's disease |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880633A (en) * | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
ES2028074T3 (en) * | 1986-06-13 | 1992-07-01 | Alza Corporation | ACTIVATION BY MOISTURE OF A TRANSDERMIC PHARMACY SUPPLY SYSTEM. |
US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
US5186939A (en) * | 1987-04-23 | 1993-02-16 | Cygnus Therapeutic Systems | Laminated composite for transdermal administration of fentanyl |
FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US5681579A (en) * | 1993-03-22 | 1997-10-28 | E.R. Squibb & Sons, Inc. | Polymeric support wound dressing |
US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
US5503844A (en) * | 1993-05-18 | 1996-04-02 | Mli Acquisition Corp. Ii | Foam laminate transdermal patch |
DE4341444C2 (en) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Active substance-containing plaster and process for its production |
US5536263A (en) * | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
US5759560A (en) * | 1995-07-27 | 1998-06-02 | Bio Med Sciences, Inc. | Silicone thermoplastic sheeting for scar treatment and useful article thereof; process of manufacture and use |
US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
TW513409B (en) * | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
DK0934078T3 (en) * | 1996-10-24 | 2003-04-14 | Alza Corp | Permeability promoters for transdermal administration of active substances, devices and processes for their preparation |
US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
US6197331B1 (en) * | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6193993B1 (en) * | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
DE19830649C2 (en) * | 1998-07-09 | 2003-04-10 | Lohmann Therapie Syst Lts | Topical patch with nonsteroidal anti-inflammatory drugs with acid group |
US6611706B2 (en) * | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
US6597946B2 (en) * | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
US6148232A (en) * | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
DE69916492T3 (en) * | 1998-12-07 | 2008-08-14 | J. Dev Ltd., Athlone | PLASTER FOR THE TRANSDERMAL APPLICATION OF VOLATILE, LIQUID ACTIVE SUBSTANCES |
US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
US7063859B1 (en) * | 1999-04-28 | 2006-06-20 | Noven Pharmaceuticals, Inc. | Barrier film lined backing layer composition and method for topical administration of active agents |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6719997B2 (en) * | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
US6673363B2 (en) * | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
EP2130538A1 (en) * | 2000-03-03 | 2009-12-09 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease |
DE10060852A1 (en) * | 2000-12-06 | 2002-06-20 | Hexal Ag | Active ingredient-impermeable cover layer or removable protective layer of a transdermal therapeutic system containing absorbents and channel formers |
US6589514B2 (en) * | 2001-04-17 | 2003-07-08 | Morinda, Inc. | Cosmetic intensive repair serum with morinda citrifolia |
US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
US6893655B2 (en) * | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
CN1571664A (en) * | 2001-10-17 | 2005-01-26 | 久光制药株式会社 | Percutaneous absorption preparations |
AU2002340232A1 (en) * | 2001-10-17 | 2003-04-28 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
US6787682B2 (en) * | 2001-11-05 | 2004-09-07 | Hollister Incorporated | Absorbent foam wound dressing |
JP2004024724A (en) * | 2002-06-28 | 2004-01-29 | Biopol Co Ltd | Micro-porous foam dressing material with multilayer structure, and production method therefor |
IL150509A (en) * | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical compositions containing donepezil hydrocholoride |
CN1214785C (en) * | 2002-08-27 | 2005-08-17 | 孙丽琴 | Yanming qingsong plaster and it preparation method |
US7439365B2 (en) * | 2003-11-17 | 2008-10-21 | Usv, Ltd. | Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil) |
US7186842B2 (en) * | 2003-02-12 | 2007-03-06 | Usv, Ltd. | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof |
BRPI0416063A (en) * | 2003-10-28 | 2007-01-02 | Noven Pharma | transdermally drug delivery composition, method of producing the transdermally drug delivery composition and flow control method of a medicament of a dermal drug delivery composition |
US20080138388A1 (en) * | 2005-02-04 | 2008-06-12 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal Absorption Patch |
CN101460156B (en) * | 2006-05-08 | 2011-06-08 | 帝国制药株式会社 | Tansdermally absorbable preparation comprising anti-dementia agent |
JP5097359B2 (en) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | Donepezil transdermal preparation |
KR101408488B1 (en) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
WO2013078608A1 (en) * | 2011-11-29 | 2013-06-06 | Ziqiang Gu | Donepezil pamoate and methods of making and using the same |
-
2009
- 2009-08-31 AU AU2009300184A patent/AU2009300184A1/en not_active Abandoned
- 2009-08-31 MX MX2011002260A patent/MX2011002260A/en not_active Application Discontinuation
- 2009-08-31 WO PCT/US2009/055542 patent/WO2010039381A1/en active Application Filing
- 2009-08-31 CA CA2733265A patent/CA2733265A1/en not_active Abandoned
- 2009-08-31 EP EP09818191A patent/EP2328582A4/en not_active Withdrawn
- 2009-08-31 CN CN200980138160XA patent/CN102164601A/en active Pending
- 2009-08-31 JP JP2011530087A patent/JP2012504163A/en active Pending
- 2009-08-31 BR BRPI0917862A patent/BRPI0917862A2/en not_active Application Discontinuation
- 2009-08-31 US US12/551,231 patent/US20100080842A1/en not_active Abandoned
- 2009-09-28 AR ARP090103720A patent/AR073696A1/en not_active Application Discontinuation
- 2009-09-29 TW TW098132814A patent/TW201029653A/en unknown
-
2011
- 2011-01-31 IL IL210970A patent/IL210970A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20050260255A1 (en) * | 2002-08-28 | 2005-11-24 | Takaaki Terahara | Adhesive patch |
US20080044461A1 (en) * | 2006-08-17 | 2008-02-21 | Valia Kirti H | Transdermal methods and systems for treating Alzheimer's disease |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012043801A1 (en) * | 2010-09-30 | 2012-04-05 | 積水メディカル株式会社 | Patch |
JPWO2012043801A1 (en) * | 2010-09-30 | 2014-02-24 | 積水メディカル株式会社 | Patch |
JP5850371B2 (en) * | 2010-09-30 | 2016-02-03 | 積水メディカル株式会社 | Patch |
EP2785691A4 (en) * | 2011-11-29 | 2015-09-30 | Ziqiang Gu | Donepezil pamoate, preparation method and its use |
US9353059B2 (en) | 2011-11-29 | 2016-05-31 | Zi-Oiang Gu | Donepezil pamoate, method of preparation and use thereof |
US10272031B2 (en) | 2011-11-29 | 2019-04-30 | Zi-Qiang Gu | Memantine pamoate, method of preparation and use thereof |
US10478395B2 (en) | 2011-11-29 | 2019-11-19 | Zi-Qiang Gu | Pamoate salts and methods of use |
US10952958B2 (en) | 2011-11-29 | 2021-03-23 | Zi-Qiang Gu | Donezil pamoate, method of preparation and use thereof |
Also Published As
Publication number | Publication date |
---|---|
MX2011002260A (en) | 2011-04-07 |
CN102164601A (en) | 2011-08-24 |
CA2733265A1 (en) | 2010-04-08 |
TW201029653A (en) | 2010-08-16 |
AU2009300184A1 (en) | 2010-04-08 |
IL210970A0 (en) | 2011-04-28 |
US20100080842A1 (en) | 2010-04-01 |
JP2012504163A (en) | 2012-02-16 |
EP2328582A1 (en) | 2011-06-08 |
BRPI0917862A2 (en) | 2015-11-24 |
EP2328582A4 (en) | 2012-02-22 |
AR073696A1 (en) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100080842A1 (en) | Transdermal extended-delivery donepezil compositions and methods for using the same | |
US20090291127A1 (en) | Transdermal anti-dementia active agent formulations and methods for using the same | |
JP5906302B2 (en) | Transdermal composition comprising an agent layer and an agent conversion layer | |
JP6336476B2 (en) | Compositions and methods for transdermal delivery of hormones and other drugs | |
EP2563347B1 (en) | Propynylaminoindan transdermal compositions | |
US20100178307A1 (en) | Transdermal anti-dementia active agent formulations and methods for using the same | |
CN106413695B (en) | Rivastigmine transdermal compositions and methods of use thereof | |
US9827207B2 (en) | Propynylaminoindan transdermal compositions | |
CN113382724A (en) | Patch preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980138160.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09818191 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009818191 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009300184 Country of ref document: AU Ref document number: 590812 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2733265 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201100151 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2009300184 Country of ref document: AU Date of ref document: 20090831 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/002260 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020117006584 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011530087 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: PI0917862 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110215 |